Lupin Limited (Lupin) has announced the launch of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg in the United States following the approval for its Abbreviated New Drug Application from the U.S. FDA as bioequivalent to Xigduo® XR for the indications in the approved labeling.
Lupin Launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the US
IMT News Desk
·
1 min read